Patient Engagement In Clinical Trials Needs More FDA Guidance, Stakeholders Say
Executive SummaryIndustry urges US FDA guidance on developing plain language summaries, which could help improve the release of clinical trial results to patients.
You may also be interested in...
Recent Q&A draft guidance is aimed at assisting sponsors in planning and conducting risk-based approaches to monitoring, but ACRO’s Doug Peddicord says agency needs to take a more straightforward, proactive approach to encouraging the move away from 100% source data verification.
The European pharmaceutical trade group EFPIA says an “initial pilot” program should be launched to test the value and impact of the draft EU guideline on presenting lay summaries of clinical trial results. The group believes that the guideline should be reviewed following the pilot, as complying with it in its current form would result in companies shelling out “significant additional resources.”
The latest drug development news and highlights from our US FDA Performance Tracker.